AMRX Earnings Prediction
The chart below shows how AMRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AMRX sees a -3.85% change in stock price 10 days leading up to the earnings, and a -1.36% change 10 days following the report. On the earnings day itself, the stock moves by +2.80%. This data can give you a slight idea of what to expect for the next quarter's release.
AMRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
730.52M
18.40%
3.99%
Gross Margin
35.98%
16.93%
-6.23%
Operating Margin
10.78%
94.23%
-13.76%
Net Margin
-2.84%
-81.23%
-270.06%
EPS
-0.10
-75.00%
--
No Data Available
AMRX Earnings Analysis
Amneal Pharmaceuticals Inc Corporation (AMRX.N) Earnings Conference Call
Positive
Revenue and EBITDA Growth: Amneal Pharmaceuticals, Inc. achieved double-digit revenue and adjusted EBITDA growth in 2024, with total revenues reaching $2.8 billion, a 17% increase year-over-year.
Successful Product Launch: The company successfully launched Crexent, a new treatment for Parkinson’s disease, which has exceeded initial market share expectations, reaching about 1% in just four months.
Specialty Business Growth: The specialty business grew 14% in 2024, with a goal to exceed $500 million by 2027, driven by Crexent and other branded products.
Weight Loss Market Entry: Amneal entered the high-growth weight loss and obesity market through a collaboration with Medcera, positioning itself as a preferred global supplier and aiming to capitalize on a projected $150 billion market by 2030.
Affordable Medicine Revenue Growth: The affordable medicine segment generated $1.7 billion in revenue, growing 15% due to new launches and a diversified portfolio, with the injectables business expanding rapidly.
Biosimilars Revenue and Opportunities: Biosimilars generated $126 million in revenue in 2024, with plans for additional filings and launches, including a significant opportunity with omalizumab targeting a $2.8 billion market.
RevCare Segment Growth: The RevCare segment grew 25% in 2024, reflecting strong performance across distribution and government channels, with expectations for continued double-digit growth.
Debt Reduction and Leverage Improvement: Amneal Pharmaceuticals, Inc. reduced net leverage to 3.9 times, ahead of its target, and paid down $182 million of gross debt in 2024, demonstrating strong financial management and cash flow generation.
Negative
Earnings Miss Report: Amneal Pharmaceuticals, Inc. missed earnings expectations with a reported EPS of $-0.10031, while expectations were $0.15.
Revenue Growth vs. EPS Decline: Despite strong revenue growth of 18% in Q4, the adjusted EPS declined by $0.02 due to higher interest expenses.
Specialty Segment Revenue Decline: The company anticipates a significant revenue drop in the specialty segment due to the loss of exclusivity for Rytary, projecting sales between $120 and $140 million for 2025, down from previous levels.
Flat Gross Margins: The adjusted gross margins for 2025 are expected to remain flat at 41% to 42%, indicating potential challenges in improving profitability.
Legal Costs Impacting Cash Flow: The company is facing ongoing legal costs, with potential settlement costs of approximately $25 million expected in 2025, which could impact cash flow.
Net Leverage Reduction Efforts: While the company has reduced net leverage to 3.9 times, it still aims to lower it further, indicating ongoing financial pressure.
AMRX FAQs
How does AMRX typically perform around its earnings report dates?
Is Amneal Pharmaceuticals Inc (AMRX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AMRX Earning Call Sentiment
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2024 Earnings Call Transcript
AMRX.N
1.61%Positive
Amneal's earnings call highlights strong financial performance with 18% revenue growth and expansion in biosimilars and specialty segments. Despite some challenges like Rytary LOE and supply chain issues, the company has a resilient strategy. The collaboration with Metsera and Crexent's successful launch are positive catalysts. The Q&A reveals optimistic management sentiment and strategic investments in biosimilars. The market cap suggests moderate stock price sensitivity. Overall, the positive financial results, strategic expansion, and optimistic guidance outweigh the concerns, predicting a 'Positive' stock price movement (2% to 8%) over the next two weeks.
